New Delhi: AI-driven molecular diagnostics are ushering in a new era of precision oncology, challenging the long-standing "one-size-fits-all" approach to cancer care. Dr. Manjiri Bakre , CEO and Founder, OncoStem Diagnostics discusses with ETHealthworld's Rashmi Mabiyan Kaur on how her company's AI-powered prognostic test, CanAssist-Breast (CAB), is revolutionising treatment decisions by offering a personalised risk prediction for cancer recurrence for early-stage breast cancer patients.

Q.How does CanAssist-Breast use AI to analyse a patient's tumour and make a critical prediction about recurrence risk?

CanAssist-Breast (CAB) uses AI to predict whether a patient’s breast cancer is likely to recur by combining tumour biology with traditional clinical features. It first anal

See Full Page